MILPITAS, Calif. -
Oct. 28, 2019 -
PRLog -- NADH oxidase (Nicotinamide Adenine Dinucleotide Phosphate Oxidase, NOX) is a homotetrameric flavoenzyme that catalyzes the oxidation of NADH by molecular oxygen to yield NAD+ . NOX is one of the well-known cancer biomarkers and is shown to be stimulated by growth factors and hormones. Several studies revealed the high activity of NADH oxidase in cancer patients as compared to healthy volunteers. More importantly, inhibition of NOX correlates with reduced cancer cell growth and induction of apoptosis. RNA interference targeting NOX expression in cancer cells effectively restored the non-cancerous phenotypes thereby further supporting the vital role of NOX in cancer progression. Furthermore, NADH oxidase is critical for the regeneration of NAD+, for use in glycolysis, and for the reduction of oxygen thereby preventing the formation of damaging reactive oxygen species. This makes NADH oxidase an attractive therapeutic target. BioVision's NADH Oxidase Activity Assay Kit couples oxidation of NADH by NOX and reduction of a colorless probe to a brightly colored product generating fluorescence at Ex/Em = 535/587 nm. The fluorescence generated is directly proportional to the NOX activity in samples. The kit can be used to determine NOX activity in a variety of sample type with a detection limit of ~ 15 µU of NOX activity per reaction.
Figure: NADH oxidase activity detected in rat liver lysate (1.3 μg total protein), HepG2 cell lysate (6 μg total protein) and Hela cell lysate (0.86 μg total protein). Assays were performed according to the kit K2019 protocol.
For more information on this assay kit visit,
https://www.biovision.com/nadh-oxidase-activity-assay-kit-fluorometric.html
